Clinical trial
EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal…
NCT00470678 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00470678 |
|---|---|
| Title | EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) |
| Official title | An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Ranibizumab (0.5 mg) in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration Over 12 Months |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Choroidal Neovascularization, Age-Related Macular Degeneration |
| Intervention type | Drug |
| Interventions | ranibizumab |
| Enrollment | 95 |
| Start date | Jun 1, 2007 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | May 8, 2007 |
| Last update posted | Nov 18, 2016 |
| Countries | South Korea, Taiwan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: